

Group



Bellevue Group results 2019

Presentation for investors, analysts and the media

Zurich, March 3, 2020

Disclaimer

This document was produced by and the opinions expressed are those of Bellevue Group AG («Bellevue») as of the date of writing and are subject to change. It has been prepared solely for information purposes and for the use of the recipient. It does not constitute an offer or an invitation by or on behalf of Bellevue to any person to buy or sell any security. Any reference to past performance is not necessarily a guide to the future. The information and analysis contained in this publication have been compiled or arrived at from sources believed to be reliable but Bellevue does not make any representation as to their accuracy or completeness and does not accept liability for any loss arising from the use hereof.

This document is not an offering prospectus pursuant to Art. 652a of the Swiss Federal Code of Obligation or a listing prospectus pursuant to the listing rules of the SWX Swiss Exchange.

This publication ist not being issued in the United States of America and should not be distributed to United States Persons or publications with a general circulation in the United States. This document does not constitute an offer or invitation to subscribe for or purchase any securities. In addition, the securities of Bellevue Group AG have not been registered under the United States Securities Laws and may not be offered, sold or delivered within the United States or to U.S. Persons absent from registration under or an applicable exemption from the registration requirements of the United States Securities Laws.



Agenda

2

3

A Summary of Fiscal 2019 André Rüegg, Group CEO

Results for Fiscal 2019 Patrik Gilli, Group CFO

Business & Strategy Update André Rüegg, Group CEO

Questions & Answers

Appendix






André Rüegg, Group CEO

Key figures 2019

Very pleasing trends across all performance metrics (excl. Bank am Bellevue)



- 1) Assets of open funds and investment mandates, excl. assets under management at BB Biotech AG
- 2) Excluding extraordinary impairments of CHF 10.9 mn
- 3) Based on operating income and expense
- 4) Based on adjusted profit and equity capital after deduction of proposed payout
- 5) Based on ordinary dividend of CHF 1.25 and share price on Dec. 31, 2019



Summary Core asset management business strong – sale of Bank am Bellevue

Strong trend in continuing asset management operations

Sale of Bank am Bellevue and SIX shares

Focus on pure-play asset management with attractive growth potential


Attractive dividend and solid return on equity (ROE)

- Operating profit rose 31% to CHF 39.8 mn (prev. year: CHF 30.4 mn)
- Operating income up 12% to CHF 103.9 mn (prev. year: CHF 92.5 mn), share of recurring income remains high at 92%
- Strong 18.1% growth in assets under management to CHF 10.6 bn and net new money inflow of CHF 422 mn.
- Execution of the sale of Bank am Bellevue still on track for the first quarter 2020
- Sale of interest in SIX Group leads to a cash flow of more than CHF 48 mn that is not recognized in profit / loss statement – most of the distributable proceeds will be returned to shareholders
- Declaration of a special dividend of CHF 2.75 per share
- An attractive and well-diversified product offering underpinned by a high level of investment competence and expertise with an outstanding, long-term track record
- Strong product development backed by high innovation raises our profile as a "House of Ideas"
- Focused business model with a clear positioning will generate more growth organic and selectively inorganic
- Steady earnings power allows us to maintain our shareholder-friendly dividend policy
- Proposed dividend of CHF 1.25 (previous year: CHF 1.10) ensures an attractive dividend yield of around 5%
- Lighter balance sheet leads to a sustained improvement in return (ROE >19%, based on adjusted net profit)



Client assets reach record-high level

Sustainable growth in assets under management, 2014 – 2019 (excl. Bank am Bellevue)



Specialized healthcare strategies

Traditional investment strategies


Alternative investment strategies

Strong increase in assets under management to a new record high of CHF 10.6 bn

- Strong increase in assets under management of more than CHF 1.6 bn or 18%, driven by market performance and new money inflows
- Despite challenging markets, sustained growth momentum from previous years on display again after the temporary softness
- Time-tested investment expertise and product range deliver steady growth
- Offering of "alternative strategies" strengthened thanks to high-quality performance track record and high innovation
- Significantly broader and well-diversified business platform translates into attractive, sustainable earnings base



Strong increase in assets under management with solid new money inflow Growth of assets under management in 2019 (excl. Bank am Bellevue)



Assets under management +18%


- Performance-driven growth of CHF 1.2 bn reflects attractive growth momentum of the product range in a long-term trend
- Solid net new money contribution of CHF 422 mn or 7.3% (excl. BB Biotech AG)

New money by asset class shows clearly distinct trends

- Still strong new money inflows into innovative healthcare strategies with structural growth momentum
- Substantial growth from differentiated alternative investments (Absolute Return, Long Short, Private Equity) thanks to new money inflows
- Traditional equity, bond and mixed strategies under pressure due to market conditions and structural factors



Further improvement in operating income from core business Growth of operating income, 2014 – 2019 (excl. Bank am Bellevue)



- Asset base related «recurring»
- Transaction and perfromance related

Significant increase in operating revenues of more than 12% to CHF 103.9 mn

- Revenues from core Asset Management segment tops CHF 100 mn mark, despite absence of operating income from Bank am Bellevue
- Asset-based income growth of 4% slightly below par, due to strong AuM growth in H2 2019 (slight time lag until resulting income flows feed through to income statement)
- Performance- and transaction driven income of CHF 6.3 mn (previous year: CHF 2.5 mn), largely fueled by alternative strategies & private equity

Still focused on the business model of recurring income

 Recurring income share of total income, > 92%, remains at a very higher level






Patrik Gilli, Group CFO

Results of continuing operations (Asset Management)

Review of operating profit and cost/income ratio (excl. Bank am Bellevue)

Operating profit CHF million



Cost/Income Ratio (CIR) 88% 69% 64% 68% 62% 67% 62% 62% 62% 62% 2013 2014 2015 2016 2017 2018 2019

Operating profit jumps to CHF 39.8 mn

- Earnings growth fueled by increase in recurring income and performance fees
- Increase in personnel expense mostly reflects higher performance-related pay
- Reduction in general operating expenses, and reclassification of occupancy expenses (IFRS 16)

Cost/Income Ratio improves to 62%

- Clearly lower CIR thanks to significant increase in earnings and proportionately slower increase in cost base
- Renewed reduction in CIR confirms the positive long-term trend
- Steady increase in efficiency possible thanks to scalable business model



Consolidated financial statements

Results of continuing operations (Asset Management)

CHF 1,000	*			
	1.131.12.2019	1.131.12.2018	Chan	ge
Management fees	95'370	92'064	3'306	4%
Performance fees	6'256	2'449	3'807	155%
Other commission income	2'318	-2'022	4'340	
thereof result from trading activities	1'240	-942	2'182	
Operating income	103'944	92'491	11'453	12%
Personnel expenses	-50'989	-45'747	-5'242	11%
thereof salaries and bonuses	-48'248	-40'696	-7'552	19%
Other operating expenses	-13'111	-16'380	3'269	-20%
thereof occupancy expenses	-731	-2'762	2'031	-74%
Operating expenses	-64'100	-62'127	-1'973	3%
Operating profit	39'844	30'364	9'480	31%
Income from other financial instruments at fair value	-2'576	4'727	-7'303	-154%
thereof valuation adjustments	-3'497	0	-3'497	
Depreciation and amortization	-5'196	-5'373	177	-3%
thereof intangible fixed assets	-2'969	-5'093	2'124	-42%
thereof rights in use	-1'943	0	-1'943	
Valuation adjustments and provisions	-7'392	0	-7'392	
Taxes	-7'808	-3'755	-4'053	108%
Group profit before tax from continuing operations	16'872	25'963	-9'091	-35%




Consolidated financial statements

Consolidated results including the results of discontinued activities (Bank am Bellevue)

CHF 1,000	~			
	1.131.12.2019	1.131.12.2018	Chan	ge
Operating income	9'982	5'588	4'394	79%
thereof result from trading activities	530	-1'001	1'531	
thereof dividend income (SIX Group AG)	4'756	1'556	3'200	206%
Operating expenses	-10'131	-11'561	1'430	-12%
Valuation adjustments and provisions	-8'199	0	-8'199	
Taxes	2'921	-17	2'938	
Group net profit from discontinued operations	-5'427	-5'990	563	-9%
Group net profit	11'445	19'973	-8'528	-43%



Equity snapshot and allocation of distributable reserves Change in equity 1.1. – 31.12.2019 (consolidated)



* incl. a.o. impairment losses of CHF 7.6 mn

** incl. change in treasury shares, revaluation of pension plan liabilities under IAS 19, exchange differences and other items

Balance sheet strength and management

Facts as of 31.12.2019 (*consolidated, after total payout for* 2020)

- Significant reduction in equity to CHF 142 mn (previous year: CHF 182 mn), mainly by distributing excess reserve capital through the declaration of a special dividend Ongoing reduction of goodwill & intangible assets, despite latest acquisitions Equity capital: simple & Sale of Bank will lower capital requirements *adequate structure* Material equity capital of a solid CHF 78 mn (previous year: CHF 114 mn incl. interest in SIX) offers continued high financial flexibility for growth initiatives (organic and inorganic) Straight forward and debt-free balance sheet Continuation of shareholder-friendly dividend policy creates sustained value for shareholders Capital that is not required for strategic purposes will be returned to shareholders – declaration of special dividend of CHF 2.75 Attractive value driver for shareholders Steady earnings performance enables 14% increase in proposed dividend to CHF 1.25 (dividend yield of 5.2%*)
 - Attractive return on equity of >19%**, thanks to disciplined capital management

* Based on ordinary dividend of CHF 1.25 and share price on Dec. 31, 2019


** Based on adjusted net profit after tax of CHF 27.8 mn





André Rüegg, Group CEO

Bellevue Group a "pure play" asset manager Our business modell as "House of Ideas"





Source: Bellevue Group, as at December 31, 2019

Bellevue Group a "pure play" asset manager Company profile and strategy

Business model = simple & clear

- Pure play asset manager
- Independent, entrepreneurial "multi-boutique"
- Active, unconstrained investment approach
- Product-centric ("attractive investment ideas")
- Unique spectrum of proven investment skills and performance
- Clearly differentiated, well-diversified product portfolio
- Understandable, scalable business model

Philosophy = *build* value

- Primacy given to investment performance
- Anticipate new investment opportunities and create ideas for clients
- Focus on innovative investment products
- Offer entry opportunities for every type of investor
- Share entrepreneurial success
- Ensure attractive value creation for all stakeholders

Client assets

CHF 10.6 bn ¹⁾

Top line

> CHF 100 mn ¹⁾

Number of employees (in FTE)

97¹⁾

Shareholders' equity

CHF 142 mn ²⁾

Market cap

CHF 322 mn

Dividend yield

5.2%

Shares held by anchor shareholders & employees

44.5%

- 1) Only continuing operations
- 2) After proposed payout



Bellevue = "House of Ideas"

- Focus on sustained earnings power and growth
- Proven performance criteria (KPIs) for business management
- Good balance between "specialty" and "diversification"
- Solid balance sheet, zero debt
- Strong base of core shareholders
- Shareholder-friendly dividend policy and attractive capital returns

Financial profile = robust & low-risk

- Independent, efficient and entrepreneurial since 1993
- Strong financial commitment from all levels of the workforce
- Investment teams enjoy a considerable degree of autonomy (no CIO/investment committees)
- Quality and innovation are growth drivers
- Trust and entrepreneurial freedom ("empowerment")

Culture - "We eat our own cooking"

Attractive offering with clearly differentiated investment expertise

Good balance between "specialty" and "diversification" - for investors and shareholders!



Specialized healthcare strategies (directional)

Investment companies

- Biotech
- Healthcare Global

Investment funds

- Biotech
- Medtech & Services
- Asia / Emerging Markets
- Healthcare Global
- ESG strategies

Mandates

- Custom fund mandates
- Institutional mandates





Alternative investment strategies (uncorrelated)

Private equity funds

- Biotech ventures funds
- Private Equity DACH Fund (new)

Private equity investments


Private equity direct investments (new)

Absolute Return strategies

- Global Macro (alternative UCITS)
- Market-neutral investment strategies (rules-based)

Mandates

- Custom fund mandates
- Institutional mandates





Traditional investment strategies (diversified)

Specialized growth strategies

- Entrepreneur strategies (CH/EU)
- Frontier markets (Africa)

Defensive investment strategies

Globale value strategies

Fixed income strategies

Global fixed income strat. (unconstrained)

Multi-asset strategies

- Defensive / dynamic multi-asset strategies
- Long/Short multi-asset strategies

Mandates

- Custom fund mandates
- Institutional mandates





Business model and positioning enable more growth Our growth drivers



Group

Solid investment performance Excellent competitiveness, client benefit, stability



- 90% of AuM in 1st quartile or 2nd quartile in 2019
- 82% of AuM in 1st and 2nd quartile over 3 years
- 90% of AuM in 1st and 2nd quartile since inception
- 76% of AuM in 1st quartile since inception
- 72% of AuM beat benchmark in 2019
- 77% of AuM beat benchmark over 3 years
- 76% of AuM beat benchmark since inception
- 16 of 19 lead portfolio managers in charge since date of launch
- No portfolio manager changes in 2019
- Very low fluctuation rates for >10 years
- Steady recruitment of new investment professionals and young talents


* Outperformance after expenses, based on institutional share classes



BB Biotech – growing in a challenging market environment

Flagship product with convincing long-term performance track record

10Y performance (in CHF) Indexed in %



30% 20% September 2018: Index inclusion SPI & SMIM 10% 0% -10% -20% -30% -40% 2016 2010 2015 2017 2009 2011 2018 2019 2013 MSCI World Healthcare Index BB BIOTECH SHS BB BIOTECH NAV NBI

Performance comparison

	2019	3 years	5 years
BB Biotech shares	18.5%	38.1%	77.2%
BB Biotech NAV	23.4%	30.2%	25.1%
NBI Index	23.0%	31.8%	18.6%
MSCI World Healthcare	21.2%	43.8%	46.2%
Total Return in CHF			

лаї кеципі іп Сп

Summary

- Positive trend in a generally favorable stockmarket environment
- 3 portfolio holdings were takeover targets in 2019: Celgene, Audentes and Alder
- Normalization of share premium within a range from 5% to 12% in December
- Nomination of Susan Galbraith and Mads Krogsgaard Thomsen as directors to broaden expertise on Board of Directors
- No change in dividend policy (5% yield)



Development of the discount/premium to the NAV

Performance quality an unconditional requirement for growth

Examples of product strategies with high new money inflows (1/2)

BB Healthcare Trust Plc

Performance since inception (in GBP)

Investment trust that invests in the global healthcare space


170 150 130 100 Dec-16 Jun-17 Dec-17 Jun-18 Dec-18 Jun-19 Dec-19 BB Healthcare Trust — MSCI World Healthcare Index

	2019	ITD
BB Healthcare Trust – GBP	22.6%	53.5%
MSCI World Healthcare Net Total Return Index	18.4%	47.2%

BB Adamant Medtech & Services

Equity fund investing in companies in the medical technology & services sector

Performance since inception (in EUR)



	2019	3 years	5 years	ITD
BB Adam. Medtech & Serv. – EUR-I	29.4%	75.5%	110.3%	369.6%
MSCI World HC Net Total Return Index	25.7%	42.2%	62.0%	346.5%




Source: Bloomberg, Bellevue Group, as at December 31, 2019

Performance quality an unconditional requirement for growth

Examples of product strategies with high new money inflows (2/2)

BB Adamant Digital Health

Equity fund investing in companies in the digital & healthcare sector





	2019	ITD
BB Adamant Digital Health – USD-I	18.1%	36.8%

Performance since inception (in USD)

BB Global Macro

UCITS V regulated absolute return strategy with daily liquidity





------ BB Global Macro I EUR

	2019	3 years	5 years	ITD
BB Global Macro – EUR-I	7.4%	8.6%	20.3%	45.4%



Another surge of innovation on the product front

Snapshot of the new investment products

BB Adamant Sustainable Healthcare Bellevue Funds (Lux)

- World's first healthcare fund with a focus on sustainability
- Global equity portfolio consisting of 40 positions based on a time-tested investment process
- Profits from the pent-up demand in emerging market countries and innovation in industrialized nations
- Cooperation with a global ESG specialist



 Meets strict standards for sustainable financial products in accordance with



Inception date: 30.06.2018

^{B|B} StarCapital Long/Short Allocator

- Established, worldwide multi-asset solution that features a long/short approach
- Upside potential from selection of inexpensive top-quality stocks (typically 70%)
- Protected from heavy losses by strict hedging at index level (typically -30%) and bond/precious metals allocation
- Active management of asset allocation with a neutral net equity weighting of 40% (long bias)
- UCITS V regulated absolute return strategy with daily liquidity
- Long-term target return of 5% p.a. with a volatility of 5% p.a.

Strategy adjustment: 31.05.2019



Expansion in Private Markets business – organic...

Strong performance by BB Pureos Bioventures Fund

Experienced team with proven sector expertise



Dr. Klaus Breiner Managing Partner



Dr. Ximing Ding Analyst



Dr. Dominik Escher

Managing Partner

Dr. Michael Motz Entrepreneur in Residence



Dr. Martin Münchbach Managing Partner



Dr. Alexander Breidenbach Entrepreneur in Residence

Initial investments in domestic/foreign markets



AMEPHARMA




novaGo

Clear investment focus

- Clear focus on drug development with a focus on innovative biologics and platforms
- Risk capital primarily invested in promising young companies based in Europe/Switzerland

Solid investor based with recognized industry experts

- Commitment of strategic investors from the US and Asia and institutional as well as private Swiss investors
- Currently CHF 160 mn in capital (target size: CHF 200 mn)



Group

Expansion in Private Markets business – ... and inorganic

Acquisition of adbodmer AG and Realwerk AG as additional growth catalysts

Experienced team with high level of professional expertise



Dr. Adriana Ospel-Bodmer Founder & Board Director





Olivier Franscella Principal



Dr. Kuno Jung Managing Director



Lionel Fracheboud **Project Manager**



Rainer Hoegg **Co-Managing Director**

adbodmer

RFAI WFRK AG

- **Profile & Competencies**
- Direct equity investments for wealthy individuals and families
- Transaction advisory services
- Direct equity investments

New strategic unit

- Consolidation of activities within the newly created business unit Bellevue Private Markets AG
- Jan Kollros new member of Group Executive Board


Outlook for 2020

- Selective expansion of investment opportunities in DACH region
- Gradual expansion of exclusive investor network
- Build up proprietary deal flow and investment management activities
- Launch of new private equity fund in 2020 planned



Client and growth momentum

Ongoing expansion of client network and development of new markets



Strong growth in "core markets" across all segments

- Switzerland, Germany, UK
- Active through local subsidiaries

Good growth momentum in strategic secondary markets

Spain, Austria, Luxembourg

Asian markets on the rise

- Taiwan, Korea, China (with local products and/or venture investors)
- Singapore, Hong Kong (as Asian hubs)

Entry into new markets 2020

Italy, Israel

US market

• "Under observation"



Bellevue - firmly committed to ESG investing

Sustainable and responsible investing with and in Bellevue

Corporate values

«Bellevue Group commits to sustainable, responsible and values-driven business practices.»*



* Signing of the UN PRI guidelines by Bellevue Asset Management in August 2019

^{B|B} Bellevue Group

RESEARCH INC.

SUSTAINALYTICS

Summary Strategic developments and priorities 2020

Achievements 2019

- Strengthened AuM base with high earnings quality
- Solid organic growth thanks to good investment performance and inflow of new client money
- Acquisition of adBodmer another "catalyst" for developing direct equity investment business
- Sale of interest in SIX creates financial flexibility
- Sale of Bank am Bellevue initiated and on track



Sale of Bank am Bellevue:

- Closing of the transaction in Q1 and transition in H1
- Use of proceeds from the sale of Bank am Bellevue and SIX shares

Consolidation as a "pure-play" asset manager

- Structural and personnel adjustments
- Greater focus on products and performance
- Evolution & turnaround StarCapital

Continue growth trajectory:

- Expand "Private Markets" unit
- Create new ideas & innovation
- Expand client network & enter new country markets



2 Assets under management (AuM)

5 Return on equity



Strategic focus on pure asset management

- Continuing development of highly specialized sector strategies ("healthcare")
- Differentiate and scale up range of welldiversified traditional strategies
- Expand uncorrelated investment solutions in the fields of alternative investments and direct equity investments
- Sustained strengthening of business and income flows
- Deploy excess capital to growth initiatives

 organic and selectively inorganic







1 Recurring revenues



Performance criteria 2020 – solid basis for future growth Long-term goals reiterated



- Recurring revenues the main focus of the business model
- Share of recurring revenues in a range from >90% targeted
- Steady expansion of business base targeted, but market-dependent
- Organic new money growth in a range of 5-10% p.a.
- Short-term target range of 60-65% (adjusted, i.e. excl. extraordinary effects)
- Medium-term target <60%
- Proportionately faster growth thanks to economies of scale in business model
- Stable and growing operating profits ensure steady dividend policy
- Continuation of shareholder-friendly dividend policy
- Attractive return on equity of >15%, thanks to strict capital management
- Most investment strategies beat their benchmark
- Most investment strategies in 1st and 2nd quartile of their competitive universe

Why turn to Bellevue Group? Highlights Bellevue Group

"Pure" asset manager with a clear and simple business model

Attractive offering with clearly differentiated investment expertise

Robust and low-risk financial profile

Significant potential for further growth

- Independent, efficient, entrepreneurial management style ever since it was established in 1993
- "
 "Multi-boutique" with unique range of investment competencies and good balance between
 "specialty" and "diversification"
- Simple and straightforward business model with a sharp focus on quality and value creation
- Active and unconstrained investment approach
- Excellent long-term track record of investment strategies with above-average returns
- "House of Ideas" Differentiated product offering and ability to create new ideas create value for the client
- Sustainable earnings power (high level of recurring income) with attractive margins
- Solid balance sheet, zero debt
- Shareholder-friendly dividend policy and attractive capital returns
- 44.5% of outstanding shares held by core shareholders and employees
- Agile, highly scalable business model creates further opportunities for profitable growth
- Competitive performance and service quality combined with highly attractive, innovative product range enables sound expansion of business and income flows
- Experience, track record and financial leeway for inorganic growth already in place






Questions & Answers




Bellevue Group a "pure play" asset manager Consistent organization – "Multi-boutique" with 3 centers of excellence



Source: Bellevue Group, as of December 31, 2019

Bellevue Group a "pure play" asset manager Growth story 2014 - 2019





Business Profile & Strategy Organizational stability, continuity and growth



"We eat our own cooking"

- Portfolio managers and key employees have a personal stake in the performance of our investment vehicles
- Our corporate culture is shaped by the independent and entrepreneurial way we think and act

A stable workforce


- Bellevue has a low employee turnover rate
- High commitment from key employees and talents at all units

On a growth track

• Expansion of its international presence in Zurich, London and Frankfurt is enlarging its talent pool



Business Profile & Strategy Structure of the shareholder base as of December 31, 2019




- Strong commitment of core shareholders
- Substantial increase in management/ employee shareholders (31.12.2018: 12.5%)
- Base of institutional shareholders is steadily growing
- Very transparent shareholder base: >88% registered (2,041 shareholders)
- Shareholder-friendly dividend policy unchanged, strengthening sense of continuity



Business Profile & Strategy

Strong performance vs. CH-Indices and other asset manager

Performance in CHF (5 years) Rebased in %




Market capitalization as of 31.12.2019 CHF 322 mn Proposed dividend for 2019 CHF 1.25 Dividend yield as of 31.12.2019 5.2%



Source: Bloomberg, Bellevue Group, as at December 31, 2019


^{*} additional proposed special dividend 2019 of CHF 2.75

Business Profile & Strategy Milestones in the Group's history





Bellevue - firmly committed to ESG investing Major ESG investment milestones







Solid development of investment performance 1/2 Performance of the investment strategies 2019

Absolute performance, in base currency

BB Entrepreneur Switzerland (CHF) **BB** Adamant Medtech & Services (EUR) **BB** Adamant Biotech (USD) BB Entrepreneur Europe Small (EUR) BB Entrepreneur Swiss Small & Mid Lux (CHF) BB Adamant Global Biotech (CHF) BB Healthcare Trust - NAV (GBP) BB Adamant Sustainable Healthcare (USD) BB Adamant Asia Pacific Healthcare (USD) BB Adamant Healthcare Index (USD) BB Biotech AG - NAV (CHF) BB Adamant Global Medtech & Services (CHF) BB Adamant Global Healthcare Index (CHF) **BB** Entrepreneur Europe (EUR) BB Adamant Digital Health (USD) BB Adamant Emerg. Market Healthcare (USD) **BB** African Opportunities (EUR) BB Adamant Global Generika (CHF) **BB Global Macro (EUR)** BB Europe Equity Market Neutral (EUR)*



Relative performance, in the competitive universe after




* Launched as of April 30, 2019

^{BB} Bellevue Group

Source: Bellevue Group, Bloomberg, Lipper for Investment Management/Refinitiv Data as at December 31, 2019

Solid development of investment performance 2/2 Performance of the investment strategies 2019





Consolidated balance sheet

Focus on Asset Management simplifies balance sheet structure

CHF 1,000	*		
	31.12.2019	31.12.2018	Change
Cash	87'486	190'284	-102'798
Trading portfolio assets	15'677	33'402	-17'725
Other financial assets at fair value	31'504	29'380	2'124
Goodwill and other intangible assets	63'959	68'212	-4'253
Other assets	37'618	146'081	-108'463
thereof due from customers	281	62'862	-62'581
thereof financial investments	175	53'730	-53'555
Total assets (without assets classified as held of sale)	236'244	467'359	-231'115
Assets classified as held of sale	153'707	0	153'707
Total assets	389'951	467'359	-77'408
Accrued expenses and deferred income	45'066	34'774	10'292
Other liabilities	21'499	235'704	-214'205
thereof due to customers	366	203'864	-203'498
Total liabilities (without liabilities directly associated with assets held for sale)	66'565	270'478	-203'913

thereof due to customers	366	203'864	-203'498
Total liabilities (without liabilities directly associated with assets held for sale)	66'565	270'478	-203'913
Liabilities directly associated with assets held for sale	127'624	0	127'624
Total liabilities	194'189	270'478	-76'289
Shareholders' equity	195'762	196'881	-1'119
Total liabilities and shareholders' equity	389'951	467'359	-77'408



Appendix Corporate Events & Contact

Corporate Events

March 3, 2020	Publication annual report 2019
March 24, 2020	Annual General Meeting 2020
July 30, 2020	Publication half-year report 2020

Investor Relations

Bellevue Group Phone +41 44 267 67 00 Fax +41 44 267 67 01 ir@bellevue.ch

Media Relations

Jürg Stähelin IRF Phone +41 44 244 81 51 staehelin@irf-reputation.ch André Rüegg CEO Bellevue Group Phone +41 44 267 67 10 aru@bellevue.ch Patrik Gilli CFO Bellevue Group Phone +41 44 267 72 53 pgi@bellevue.ch

Tanja Chicherio Marketing Bellevue Group Phone +41 44 267 67 07 tch@bellevue.ch

